Antibodies against GM1 in demented patients

American Journal of Alzheimer's Disease and other Dementias

Volumn 23, Issue 3, 2008, Pages 274-279

  Hatzifilippou, Eleni ^a   Koutsouraki, Ephrosini ^a   Banaki, Tania ^a   Traka, Maria ^a   Costa, Vassiliki G ^a   Baloyannis, Stavros J ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Alzheimer's disease; Anti GM1 IgM and dementia; Antibodies to GM1; Dementia; Gangliosides in dementia

Indexed keywords

GANGLIOSIDE GM1 ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMENTIA; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; POLYNEUROPATHY; SEX RATIO;

EID: 45449114632     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317508317816     Document Type: Article

References (29)

1. Kakio A., Nishimoto S., Yanagisawa K., Kozutsumi Y., Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry. 2002 ; 41: 7385-7390.
2. Yanagisawa K., Odaka A., Suzuki N., Ihara Y. GM1 ganglioside-bound amyloid β-protein (Aβ): a possible form of preamyloid in Alzheimer's disease. Nat Med. 1995 ; 1: 1062-1066.
3. Mandal PK, Pettegrew JW Alzheimer's disease: NMR studies of asialo (GM1) and trisialo (GT1b) ganglioside interactions with Abeta (1-40) peptide in a membrane mimic environment. Neurochem Res. 2004 ; 29: 447-453.
4. McLaurin JA, Franklin T., Fraser PE, Chakrabartty A. Structural transitions associated with the interaction of Alzheimer β-amyloid peptides with gangliosides. J Biol Chem. 1998 ; 273: 4506-4515.
5. Hayashi H., Kimura N., Yamaguchi H. et al. A seed for Alzheimer amyloid in the brain. J Neurosci. 2004 ; 24: 4894-4902.
6. Moschetti I. Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci. 2005 ; 62: 2283-2294.
7. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002 ; 125: 2591-2625.
8. Pitto M., Raimondo F., Zoia C., Brighina L., Ferrarese C., Masserini M. Enhanced GM1 ganglioside catabolism in cultured fibroblasts from Alzheimer's patients. Neurobiol Aging. 2005 ; 26: 833-838.
9. Corbo M., Quattrini A., Latov N., Hays AP Localization of GM1 and Gal(beta 1-3) GalNAc antigenic determinants in peripheral nerve. Neurology. 1993 ; 43: 809-814.
10. Ogawara K., Kuwabara S., Mori M., Hattori T., Koga M., Yuki N. Axonal Gullain Barrè syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000 ; 48: 624-631.
11. Asahina M., Kuwabara S., Suzuki A., Hattori T. Autonomic function in demyelinating and axonal subtypes of Gullain Barrè syndrome. Acta Neurol Scand. 2002 ; 105: 44-50.
12. Wojcik M., Ulas J., Oderfeld-Nowak B. The stimulating effect of ganglioside injections on the recovery of choline acetyltransferase activities in the hippocampus of the rat after septal lesions. Neuroscience. 1982 ; 7: 495-499.
13. Hadjiconstantinou M., Neff HN GM1 ganglioside: in vitro and in vivo trophic actions on central neurotransmitter systems. J Neurochem. 1998 ; 70: 1335-1344.
14. Koch HJ, Gürtler K., Szecsey A. Correlation of MMSE, SKT and clock test scores in patients with mild and moderate dementia. Nagoya J Med Sci. 2005 ; 67: 93-100.
15. Santacruz KS, Swagerty D. Early diagnosis of dementia. Am Fam Phys. 2001 ; 63: 703-713.
16. Gilliam FG, Kanner AM, Sheline YI Depression and Brain Dysfunction. Basingstoke, UK: Taylor & Francis ; 2005.
17. Marzanski M. On telling the truth to patients with dementia. West J Med. 2000 ; 173: 318-323.
18. Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 ; 43: 2412-2414.
19. Schott K., Wormstall H., Dietric M., Klein R., Batra A. Autoantibodies reactivity in serum of patients with Alzheimer's disease and other age-related dementias. Psychiatry Res. 1996 ; 59: 251-254.
20. Voumvourakis C., Rombos A., Konstantoulakis MM, Segditsa I., Papageorgiou C. Serum anti-GM1 and anti-GD1a antibodies in patients with motor neuron disease. Acta Neurol Scand. 1992 ; 86: 599-602.
21. Zappia M., Crescibene L., Bosco D., et al. Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand. 2002 ; 106: 54-57.
22. Dinesh K., Manvir B., Vivekanandan S., et al. IgM anti-GM1 antibody titres in patients with monomelic amyotrophy. Neurol Ind. 2006 ; 54: 399-401.
23. Chapman J., Sela BA, Wertman E., Michaelson DM Antibodies to ganglioside GM1 in patients with Alzheimer's disease. Neurosci Lett. 2003 ; 86: 235-300.
24. Iwamoto N., Suzuki Y., Makino Y., Haga C., Kosaka K., Iizuka R. Cell membrane changes in brains manifesting senile plaques: an immunohistochemical study of GM1 membranous ganglioside. Brain Res. 2003 ; 522: 152-156.
25. Carpo M., Meucci N., Allaria S., et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J Neurol Sci. 2000 ; 176: 144-150.
26. Molander-Melin M., Blennow K., Bogdanovic N., Dellheden B., Månsson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem. 2005 ; 92: 171-182.
27. Yanagisawa K. GM1 ganglioside and the seeding of amyloid in Alzheimer's disease: endogenous seed for Alzheimer amyloid. Neuroscientist. 2005 ; 11: 250-256.
28. Yanagisawa K., Matsuzaki K. Cholesterol-dependent aggregation of amyloid β-protein. Ann N Y Acad Sci. 2002 ; 977: 384-386.
29. Ariga T., Yu RK GM1 inhibits amyloid β-protein-induced cytokine release. Neurochem Res. 2004 ; 24: 219-226.